

Nordic Microbiota Meeting 2024

Program, updated 25 October 2024

Information and contact

Web page www.nordicmicrobiota.com

Email contact@nordicmicrobiota.com

Dates

Start: Tuesday 05 November 2024 at 17.00 (5PM), CET.

End: Wednesday 06 November 2024 at 18.00 (6PM), CET.

Venue

Hotel Ottilia, Bryggerens Plads 7, 1799 DK-København V, Denmark

<https://www.brochner-hotels.com/our-locations/hotel-ottilia>

Tel. +45 3338 7030. Email info@hotelottilia.dk.

Aims

Academic meeting to explore clinical and translational research in intestinal microbiome science; facilitate networking between young and experienced researchers; stimulate collaboration in microbiome research in the five Nordic countries.

Participants

Open to microbiota researchers with a clinical focus, in the Nordic countries (Norway, Sweden, Finland, Iceland, Denmark). The number of participants is restricted to 120 persons. The steering committee prioritises a balanced representation from different countries, specialties, and seniorities.

Registration

Registration has closed. All contact regarding the meeting, please write to contact@nordicmicrobiota.com.

Program



Tuesday 05 November 2024

16.00 – 17.00 Check-in; refreshments; registration

Common lounge area, level 4, with refreshments. Booklet and conference material.

17.00 – 17.15 Welcome. Outline, presentation of concept and participants

Brief introduction; house rules.

17.15 – 17.45 Meet your Nordic colleague

Interactive session: Meet a colleague you did not know on beforehand. Exchange info.

17.45 – 19.00 Session 1: Poster flash presentations

11 selected posters, organised in lobby area, level 4. Each participant chooses 4 posters to visit. Each session 10 minutes (4 min presentation, 6 min discussion), each rotation between posters 5 minutes. Snacks and drinks refill served during short rotations.

- *Malin Bergman (ab#5): Introduction of a diagnostic faecal microbiome diversity test to offer FMT to patient groups other than those with Clostridioides difficile infection*
- *Trond Flaegstad (ab#11): Long Term Azithromycin Treatment Reduces Gut Microbial Diversity in Children and Adolescents with HIV-associated Chronic Lung Disease*
- *Eveliina Munukka (ab#22): The first six years of Turku Clinical Microbiome Bank, TCMB*
- *Aswathy Narayanan Baseline (ab#23): Gut Microbiome and Metabolic Pathways as Predictors of SARS-CoV-2 Vaccine Efficacy in PLWH*
- *Andraz Nendl (ab#24): Circulating metabolites in patients with chronic heart failure are related to energy metabolism but not to gut microbiota alterations*
- *Panpan (ab#26): The gut bacterial community type of the recipient affects long-term remission of FMT in psoriatic arthritis*
- *Kristina Fruerlund Rasmussen (ab#27): Does This Fecal Microbiota Transplant Work? Quality assurance of capsule based Fecal Microbiota Transplant production*
- *Nina Rågård (ab#30): Validation methods for encapsulated faecal microbiota transplantation: a scoping review*
- *Stine Sofie Strømmand (ab#32): Effects of sulfur amino acid restriction on gut microbiota and inflammation in people with overweight and obesity: an 8-week randomized controlled dietary intervention study*
- *Maja Johanne Søndergaard Knudsen (ab#33): The effect of faecal microbiota transplantation on eradication of multidrug-resistant organisms in intestinal carriers – a multicentre, randomised, placebo-controlled, and double-blinded clinical trial.*
- *Tadas Urbonas (ab#35): Fecal microbiome transplantation for recurrent CDI: treatment efficacy and safety with oral capsules*

19.30 – 21.00 Social dinner

Carl's diner, next door, right next to the Carlsberg elephants. Social networking. Brief festive speeches.

08.00 – 08.15 Good morning; reload

Arrival in lobby level 4; post-breakfast coffee; posters are still posted in lobby area.

08.15 – 09.00 Session 2: Clinical aspects of microbiota modulation

Moderators: Lena Serrander, Johannes Hov

- *Julia König (ab#20): The effects of a 6-week probiotic intervention on gut barrier function, immune markers and symptoms in patients with diarrhoea-predominant irritable bowel syndrome*
- *Sara Ellegaard Paaske (ab#25): Improving clinical outcomes of encapsulated faecal microbiota transplantation for *Clostridioides difficile* through optimised dosing and empirical donor exclusion: a quality improvement study*
- *Trine Rounge (ab#29): The gut microbiome in colorectal cancer screening: species and genome level analyses*

09.00 – 09.45 Session 3: New indications for FMT (I)

Moderators: Dennis Sandris Nielsen, Robert Caesar

- *Pegah Abdollahi (ab#1): Can the microbiota composition impact treatment outcome in multiple myeloma patients receiving first line treatment?*
- *Anna Hartikainen (ab#16): Microbial changes introduced by fecal microbiota transplantation in irritable bowel syndrome*
- *Katrine Lundby Høyer (ab#18): Faecal microbiota transplantation for patients with diabetes type 1 and severe gastrointestinal neuropathy (FADIGAS): A randomised, double-blinded, placebo-controlled trial*

09.45 – 10.00 Short break

10.00 – 11.00 Session 4: Break-out sessions

Break-out presentation and discussions (3 in parallel – allocation to sessions on site)

1: Basic science

- *Camilla Hartmann Friis Hansen (ab#14): Birth by cesarean section exacerbates asthma and metabolic disease in a microbiota-dependent manner*
- *Petra Hanzely (ab#15): The impact of human gut microbiota on a mouse model of biliary disease - experiences from Norway*
- *Johannes Skræp (ab#31): Examining the Role of the Microbiome-Immune Axis in the Development of Systemic Lupus Erythematosus*

2: FMT methods

- *Berta Bosch (ab#6): Development of a Protocol for Anaerobic Preparation and Banking of Fecal Microbiota Transplantation Material: Evaluation of Bacterial Richness in the Cultivated Fraction*
- *Mette Mejlby Hansen (ab#13): Encapsulated donor faeces for faecal microbiota transplantation: the Glyprotect protocol*

3: Clinical protocols

- *Nanna Sutter Rolighed (ab#28): Faecal Microbiota Transplantation against chronic diarrhea in Patients with Systemic Sclerosis – a randomized, double-blinded, safety and pilot-efficacy study*
- *Aron Clementsen (ab#9): PhageX: Next-generation bacteriophage therapy for treating gut-related diseases*

11.00 – 11.30 Break with coffee and delights

Lounge area

11.30 – 12.30 Keynote lecture, with discussion

Challenges and opportunities in intestinal microbiota transplantation (IMT/FMT)

Benjamin H. Mullish, Imperial College London, United Kingdom

12.30 – 13.30 Lunch (next door)

13.30 – 14.15 Session 5: Biomarkers and metabolites

Moderators: Reetta Satokari, Marius Trøseid

- *Xiangning Bai (ab#2): Microbiome profiling reveals gut bacterial species associated with rapid lung function decline in people with HIV*
- *Louise Thingholm (ab#34): Detecting microbial enzymes responsible for modifying patient drug response*
- *Rima Chakaroun (ab#8): Comprehensive multi-omics analysis reveals connections between metabolic obesity, adipose tissue structure, and microbiome composition*

14.15 – 15.00 Session 6: Mechanisms in microbiota-directed therapies

Moderators: Robert Brummer, Piotr Nowak

- *Lotte Eriksen (ab#10): Alterations in peripheral Tregs and NKT cells after faecal microbiota transplantation in patients with recurrent *Clostridioides difficile* infection*
- *Maria Maseng (ab#21): Longitudinal Changes in Gut Microbiota During the First Year following diagnosis of Inflammatory Bowel Disease– the IBSEN III study*
- *Ruta Inciuraitė (ab#19): Host-microbiota interaction studies in vitro: from bacterial products to living microorganisms*

15.00 – 15.30 Break – coffee and delights

15.30 – 15.45 Session 7: Regulation of microbiome therapies

Brief update on competent authority regulation of substances of human origin (SoHO).

15.45 – 16.30 Session 8: New indications for FMT (II): anorexia nervosa

Moderators: Simon Baunwall, Perttu Lahtinen

- *Kenneth Barfod (ab#4): Fecal Microbiota Transplantation: A Novel Approach to Anorexia Nervosa Treatment with Insights from Animals and a Feasibility Trial*
- *Siv Kjølrsrud Bøhn (ab#7): The NORMA-study: Gut microbiota alterations in anorexia nervosa - paving the way for personalized prebiotic treatment strategies*
- *Stein Frostad (ab#12): Fecal microbiota transplantation in anorexia nervosa*

16.30 – 17.00 Concluding remarks and adjourn

17.00 – 18.00 Wine reception; departure

Organising committee and research environments



Norway

Johannes E.R. Hov (clinical gastroenterology, microbiota research), Oslo University Hospital

Kjetil Garborg (clinical gastroenterology, microbiota research), Oslo University Hospital

Marius Trøseid (infectious diseases, microbiota research), Oslo University Hospital

Research environments

- Oslo University Hospital: Clinical gastroenterology; epidemiology; mechanisms, <https://www.ous-research.no/dg/>, <https://www.med.uio.no/helsam/english/research/projects/refit-2/index.html>, <https://www.med.uio.no/helsam/english/research/environments/clinical-effectiveness/index.html>
- UiT The Arctic University of Norway: Clinical trials, FMT in irritable bowel syndrome and experimental conditions, <https://uit.no/research/gnu>

Sweden

Lena Serrander (infectious diseases, microbiome therapies), Linköping University Hospital

Piotr Nowak (basic science, FMT mechanisms, infectious diseases), Karolinska Institute and Karolinska University Hospital

Robert Caesar (Intestinal microbiota basic research), Gothenburg University

Robert Jan Brummer (FMT mechanisms), Örebro University

Research environments

- Gothenburg: Microbiome research (Fredrik Bäckhed group), <https://backhedlab.org>, <https://www.gu.se/en/sahlgrenska-akademin/our-research>
- Karolinska Institute, Stockholm (Piotr Nowak), Team Microbiota Inflammation, <https://ki.se/en/research/environments/team-microbiota-inflammation#tab-start>
- Örebro University (Robert Brummer), Nutrition-Gut-Brain Interactions Research Centre (NGBI), <https://www.oru.se/NGBI>
- Linköping University (Lena Serrander), <https://liu.se/en/employee/lense86>

Denmark

Christian Erikstrup (clinical immunology, faeces donor recruitment and screening), Aarhus University Hospital

Christian Lodberg Hvas (gastroenterology, FMT studies), Aarhus University Hospital

Dennis Sandris Nielsen (biology, intestinal virome research), University of Copenhagen

Nina Rågård (gastroenterology, basic and clinical FMT studies), Aarhus University Hospital

Sara Ellegaard Andreasen (microbiome therapies quality improvement), Aarhus University Hospital

Simon Mark Dahl Baunwall (gastroenterology, FMT studies), Aarhus University Hospital

Research environments

- Aarhus University: Clinical FMT studies, donor studies, <https://cefta.au.dk> and <https://clin.au.dk/research/research-areas/liver-and-gut>
- Copenhagen University, KU Food: Food Microbiology, Gut Health, and Fermentation; Virome therapy (Dennis Sandris Nielsen); https://food.ku.dk/english/research_at_food/sections/microbiology/ and Copenhagen Gut Microbiome Hub, <https://cphgut.ku.dk>

Finland

Perttu Arkkila (gastroenterology, FMT studies), Helsinki University

Perttu Lahtinen (gastroenterology, FMT studies), Lahti Regional Hospital

Reetta Satokari (clinical microbiology), Helsinki University

Research environments

- University of Helsinki, Faculty of Medicine, Human Microbiome Research, <https://www.helsinki.fi/en/faculty-medicine/research/research-programs-unit/human-microbiome-research-humi>

Iceland

Stefán Haraldsson (gastroenterology), Reykjavik University Hospital

Research environment

- Clinical gastroenterology, Landspítali Reykjavik, <https://www.landspitali.is>